-
-
-
-
-
-
-
Rocket Pharmaceuticals sells priority review voucher for $180 million
-
-
-
-
-
-
-
FDA accepts Rocket Pharmaceuticals' resubmitted gene therapy application
-
-
-
-
-
-
-
Rocket Pharmaceuticals cuts workforce 30% to focus on heart treatments
-
-
-
-
-
-
-
Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease
-
-
-
-
-
-
-
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
Rocket Pharmaceuticals (RCKT) Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
-
-
-
-
-
-
-
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI⢠(marnetegragene autotemcel; marne-cel)
-
1,177,147 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

